English
简体中文
Total: £ 56.28
Published Date: 2026-01-20 | Pages: 98 | Tables: 100 | Pharma & Healthcare
The global Duvelisib for Relapsed CLL/SLL market was valued at US$ 228 million in 2025 and is anticipated to reach US$ 571 million by 2032, at a CAGR of 14.2% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Duvelisib for Relapsed CLL/SLL competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
DUVELISIB is a medicine that targets proteins in cancer cells and stops the cancer cells from growing. It treats chronic lymphocytic leukemia and small lymphocytic lymphoma.
The North American market for Duvelisib for Relapsed CLL/SLL is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Duvelisib for Relapsed CLL/SLL is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Duvelisib for Relapsed CLL/SLL include Secura Bio, CSPC, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Duvelisib for Relapsed CLL/SLL market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Duvelisib for Relapsed CLL/SLL. The Duvelisib for Relapsed CLL/SLL market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Duvelisib for Relapsed CLL/SLL market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Duvelisib for Relapsed CLL/SLL manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Secura Bio
CSPC
Segment by Type
25mg
15mg
by Application
Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Duvelisib for Relapsed CLL/SLL manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Duvelisib for Relapsed CLL/SLL sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Duvelisib for Relapsed CLL/SLL Market Overview
1.1 Product Definition
1.2 Duvelisib for Relapsed CLL/SLL by Type
1.2.1 Global Duvelisib for Relapsed CLL/SLL Market Value by Type: 2025 vs 2032
1.2.2 25mg
1.2.3 15mg
1.3 Duvelisib for Relapsed CLL/SLL by Application
1.3.1 Global Duvelisib for Relapsed CLL/SLL Market Value by Application: 2025 vs 2032
1.3.2 Chronic Lymphocytic Leukemia (CLL)
1.3.3 Small Lymphocytic Lymphoma (SLL)
1.4 Global Duvelisib for Relapsed CLL/SLL Market Size Estimates and Forecasts
1.4.1 Global Duvelisib for Relapsed CLL/SLL Revenue 2021–2032
1.4.2 Global Duvelisib for Relapsed CLL/SLL Sales 2021–2032
1.4.3 Global Duvelisib for Relapsed CLL/SLL Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Duvelisib for Relapsed CLL/SLL Market Competition by Manufacturers
2.1 Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Manufacturers (2021–2026)
2.2 Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Duvelisib for Relapsed CLL/SLL Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Duvelisib for Relapsed CLL/SLL, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Duvelisib for Relapsed CLL/SLL, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Duvelisib for Relapsed CLL/SLL, Product Types and Applications
2.7 Global Key Manufacturers of Duvelisib for Relapsed CLL/SLL, Date of Entry into the Industry
2.8 Global Duvelisib for Relapsed CLL/SLL Market Competitive Situation and Trends
2.8.1 Global Duvelisib for Relapsed CLL/SLL Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Duvelisib for Relapsed CLL/SLL Players Market Share by Revenue
2.8.3 Global Duvelisib for Relapsed CLL/SLL Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Duvelisib for Relapsed CLL/SLL Market Scenario by Region
3.1 Global Duvelisib for Relapsed CLL/SLL Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Duvelisib for Relapsed CLL/SLL Sales by Region: 2021–2032
3.2.1 Global Duvelisib for Relapsed CLL/SLL Sales by Region: 2021–2026
3.2.2 Global Duvelisib for Relapsed CLL/SLL Sales by Region: 2027–2032
3.3 Global Duvelisib for Relapsed CLL/SLL Revenue by Region: 2021–2032
3.3.1 Global Duvelisib for Relapsed CLL/SLL Revenue by Region: 2021–2026
3.3.2 Global Duvelisib for Relapsed CLL/SLL Revenue by Region: 2027–2032
3.4 North America Duvelisib for Relapsed CLL/SLL Market Facts & Figures by Country
3.4.1 North America Duvelisib for Relapsed CLL/SLL Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Duvelisib for Relapsed CLL/SLL Sales by Country (2021–2032)
3.4.3 North America Duvelisib for Relapsed CLL/SLL Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Duvelisib for Relapsed CLL/SLL Market Facts & Figures by Country
3.5.1 Europe Duvelisib for Relapsed CLL/SLL Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Duvelisib for Relapsed CLL/SLL Sales by Country (2021–2032)
3.5.3 Europe Duvelisib for Relapsed CLL/SLL Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Duvelisib for Relapsed CLL/SLL Market Facts & Figures by Region
3.6.1 Asia Pacific Duvelisib for Relapsed CLL/SLL Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Duvelisib for Relapsed CLL/SLL Sales by Region (2021–2032)
3.6.3 Asia Pacific Duvelisib for Relapsed CLL/SLL Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Duvelisib for Relapsed CLL/SLL Market Facts & Figures by Country
3.7.1 Latin America Duvelisib for Relapsed CLL/SLL Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Duvelisib for Relapsed CLL/SLL Sales by Country (2021–2032)
3.7.3 Latin America Duvelisib for Relapsed CLL/SLL Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Duvelisib for Relapsed CLL/SLL Market Facts & Figures by Country
3.8.1 Middle East and Africa Duvelisib for Relapsed CLL/SLL Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Duvelisib for Relapsed CLL/SLL Sales by Country (2021–2032)
3.8.3 Middle East and Africa Duvelisib for Relapsed CLL/SLL Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Duvelisib for Relapsed CLL/SLL Sales by Type (2021–2032)
4.1.1 Global Duvelisib for Relapsed CLL/SLL Sales by Type (2021–2026)
4.1.2 Global Duvelisib for Relapsed CLL/SLL Sales by Type (2027–2032)
4.1.3 Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Type (2021–2032)
4.2 Global Duvelisib for Relapsed CLL/SLL Revenue by Type (2021–2032)
4.2.1 Global Duvelisib for Relapsed CLL/SLL Revenue by Type (2021–2026)
4.2.2 Global Duvelisib for Relapsed CLL/SLL Revenue by Type (2027–2032)
4.2.3 Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Type (2021–2032)
4.3 Global Duvelisib for Relapsed CLL/SLL Price by Type (2021–2032)
5 Segment by Application
5.1 Global Duvelisib for Relapsed CLL/SLL Sales by Application (2021–2032)
5.1.1 Global Duvelisib for Relapsed CLL/SLL Sales by Application (2021–2026)
5.1.2 Global Duvelisib for Relapsed CLL/SLL Sales by Application (2027–2032)
5.1.3 Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Application (2021–2032)
5.2 Global Duvelisib for Relapsed CLL/SLL Revenue by Application (2021–2032)
5.2.1 Global Duvelisib for Relapsed CLL/SLL Revenue by Application (2021–2026)
5.2.2 Global Duvelisib for Relapsed CLL/SLL Revenue by Application (2027–2032)
5.2.3 Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Application (2021–2032)
5.3 Global Duvelisib for Relapsed CLL/SLL Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Secura Bio
6.1.1 Secura Bio Company Information
6.1.2 Secura Bio Description and Business Overview
6.1.3 Secura Bio Duvelisib for Relapsed CLL/SLL Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Secura Bio Duvelisib for Relapsed CLL/SLL Product Portfolio
6.1.5 Secura Bio Recent Developments/Updates
6.2 CSPC
6.2.1 CSPC Company Information
6.2.2 CSPC Description and Business Overview
6.2.3 CSPC Duvelisib for Relapsed CLL/SLL Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 CSPC Duvelisib for Relapsed CLL/SLL Product Portfolio
6.2.5 CSPC Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Duvelisib for Relapsed CLL/SLL Industry Chain Analysis
7.2 Duvelisib for Relapsed CLL/SLL Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Duvelisib for Relapsed CLL/SLL Production Mode & Process Analysis
7.4 Duvelisib for Relapsed CLL/SLL Sales and Marketing
7.4.1 Duvelisib for Relapsed CLL/SLL Sales Channels
7.4.2 Duvelisib for Relapsed CLL/SLL Distributors
7.5 Duvelisib for Relapsed CLL/SLL Customer Analysis
8 Duvelisib for Relapsed CLL/SLL Market Dynamics
8.1 Duvelisib for Relapsed CLL/SLL Industry Trends
8.2 Duvelisib for Relapsed CLL/SLL Market Drivers
8.3 Duvelisib for Relapsed CLL/SLL Market Challenges
8.4 Duvelisib for Relapsed CLL/SLL Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Duvelisib for Relapsed CLL/SLL Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Duvelisib for Relapsed CLL/SLL Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Duvelisib for Relapsed CLL/SLL Market Competitive Situation by Manufacturers in 2025
Table 4. Global Duvelisib for Relapsed CLL/SLL Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Duvelisib for Relapsed CLL/SLL Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Duvelisib for Relapsed CLL/SLL Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Duvelisib for Relapsed CLL/SLL Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Duvelisib for Relapsed CLL/SLL, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Duvelisib for Relapsed CLL/SLL, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Duvelisib for Relapsed CLL/SLL, Product Types and Applications
Table 12. Global Key Manufacturers of Duvelisib for Relapsed CLL/SLL, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Duvelisib for Relapsed CLL/SLL Companies by Tier (Tier 1, Tier 2, Tier 3), based on Duvelisib for Relapsed CLL/SLL Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Duvelisib for Relapsed CLL/SLL Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Duvelisib for Relapsed CLL/SLL Sales by Region (K Units), 2021–2026
Table 18. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Region (2021–2026)
Table 19. Global Duvelisib for Relapsed CLL/SLL Sales by Region (K Units), 2027–2032
Table 20. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Region (2027–2032)
Table 21. Global Duvelisib for Relapsed CLL/SLL Revenue by Region (US$ Million), 2021–2026
Table 22. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Region (2021–2026)
Table 23. Global Duvelisib for Relapsed CLL/SLL Revenue by Region (US$ Million), 2027–2032
Table 24. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Region (2027–2032)
Table 25. North America Duvelisib for Relapsed CLL/SLL Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Duvelisib for Relapsed CLL/SLL Sales by Country (K Units), 2021–2026
Table 27. North America Duvelisib for Relapsed CLL/SLL Sales by Country (K Units), 2027–2032
Table 28. North America Duvelisib for Relapsed CLL/SLL Revenue by Country (US$ Million), 2021–2026
Table 29. North America Duvelisib for Relapsed CLL/SLL Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Duvelisib for Relapsed CLL/SLL Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Duvelisib for Relapsed CLL/SLL Sales by Country (K Units), 2021–2026
Table 32. Europe Duvelisib for Relapsed CLL/SLL Sales by Country (K Units), 2027–2032
Table 33. Europe Duvelisib for Relapsed CLL/SLL Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Duvelisib for Relapsed CLL/SLL Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Duvelisib for Relapsed CLL/SLL Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Duvelisib for Relapsed CLL/SLL Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Duvelisib for Relapsed CLL/SLL Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Duvelisib for Relapsed CLL/SLL Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Duvelisib for Relapsed CLL/SLL Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Duvelisib for Relapsed CLL/SLL Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Duvelisib for Relapsed CLL/SLL Sales by Country (K Units), 2021–2026
Table 42. Latin America Duvelisib for Relapsed CLL/SLL Sales by Country (K Units), 2027–2032
Table 43. Latin America Duvelisib for Relapsed CLL/SLL Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Duvelisib for Relapsed CLL/SLL Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Duvelisib for Relapsed CLL/SLL Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Duvelisib for Relapsed CLL/SLL Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Duvelisib for Relapsed CLL/SLL Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Duvelisib for Relapsed CLL/SLL Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Duvelisib for Relapsed CLL/SLL Revenue by Country (US$ Million), 2027–2032
Table 50. Global Duvelisib for Relapsed CLL/SLL Sales (K Units) by Type (2021–2026)
Table 51. Global Duvelisib for Relapsed CLL/SLL Sales (K Units) by Type (2027–2032)
Table 52. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Type (2021–2026)
Table 53. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Type (2027–2032)
Table 54. Global Duvelisib for Relapsed CLL/SLL Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Duvelisib for Relapsed CLL/SLL Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Type (2021–2026)
Table 57. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Type (2027–2032)
Table 58. Global Duvelisib for Relapsed CLL/SLL Price (US$/Unit) by Type (2021–2026)
Table 59. Global Duvelisib for Relapsed CLL/SLL Price (US$/Unit) by Type (2027–2032)
Table 60. Global Duvelisib for Relapsed CLL/SLL Sales (K Units) by Application (2021–2026)
Table 61. Global Duvelisib for Relapsed CLL/SLL Sales (K Units) by Application (2027–2032)
Table 62. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Application (2021–2026)
Table 63. Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Application (2027–2032)
Table 64. Global Duvelisib for Relapsed CLL/SLL Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Duvelisib for Relapsed CLL/SLL Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Application (2021–2026)
Table 67. Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Application (2027–2032)
Table 68. Global Duvelisib for Relapsed CLL/SLL Price (US$/Unit) by Application (2021–2026)
Table 69. Global Duvelisib for Relapsed CLL/SLL Price (US$/Unit) by Application (2027–2032)
Table 70. Secura Bio Company Information
Table 71. Secura Bio Description and Business Overview
Table 72. Secura Bio Duvelisib for Relapsed CLL/SLL Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Secura Bio Duvelisib for Relapsed CLL/SLL Product
Table 74. Secura Bio Recent Developments/Updates
Table 75. CSPC Company Information
Table 76. CSPC Description and Business Overview
Table 77. CSPC Duvelisib for Relapsed CLL/SLL Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. CSPC Duvelisib for Relapsed CLL/SLL Product
Table 79. CSPC Recent Developments/Updates
Table 80. Key Raw Materials Lists
Table 81. Raw Materials Key Suppliers Lists
Table 82. Duvelisib for Relapsed CLL/SLL Distributors List
Table 83. Duvelisib for Relapsed CLL/SLL Customers List
Table 84. Duvelisib for Relapsed CLL/SLL Market Trends
Table 85. Duvelisib for Relapsed CLL/SLL Market Drivers
Table 86. Duvelisib for Relapsed CLL/SLL Market Challenges
Table 87. Duvelisib for Relapsed CLL/SLL Market Restraints
Table 88. Research Programs/Design for This Report
Table 89. Key Data Information from Secondary Sources
Table 90. Key Data Information from Primary Sources
Table 91. Authors List of This Report
List of Figures
Figure 1. Product Picture of Duvelisib for Relapsed CLL/SLL
Figure 2. Global Duvelisib for Relapsed CLL/SLL Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Duvelisib for Relapsed CLL/SLL Market Share by Type: 2025 & 2032
Figure 4. 25mg Product Picture
Figure 5. 15mg Product Picture
Figure 6. Global Duvelisib for Relapsed CLL/SLL Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Duvelisib for Relapsed CLL/SLL Market Share by Application: 2025 & 2032
Figure 8. Chronic Lymphocytic Leukemia (CLL)
Figure 9. Small Lymphocytic Lymphoma (SLL)
Figure 10. Global Duvelisib for Relapsed CLL/SLL Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 11. Global Duvelisib for Relapsed CLL/SLL Market Size (US$ Million), 2021–2032
Figure 12. Global Duvelisib for Relapsed CLL/SLL Sales (K Units), 2021–2032
Figure 13. Global Duvelisib for Relapsed CLL/SLL Average Price (US$/Unit), 2021–2032
Figure 14. Duvelisib for Relapsed CLL/SLL Report Years Considered
Figure 15. Duvelisib for Relapsed CLL/SLL Sales Share by Manufacturers in 2025
Figure 16. Global Duvelisib for Relapsed CLL/SLL Revenue Share by Manufacturers in 2025
Figure 17. Top 5 and Top 10 Global Duvelisib for Relapsed CLL/SLL Players: Market Share by Revenue in Duvelisib for Relapsed CLL/SLL in 2025
Figure 18. Duvelisib for Relapsed CLL/SLL Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 19. Global Duvelisib for Relapsed CLL/SLL Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 20. North America Duvelisib for Relapsed CLL/SLL Sales Market Share by Country (2021–2032)
Figure 21. North America Duvelisib for Relapsed CLL/SLL Revenue Market Share by Country (2021–2032)
Figure 22. United States Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 23. Canada Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Europe Duvelisib for Relapsed CLL/SLL Sales Market Share by Country (2021–2032)
Figure 25. Europe Duvelisib for Relapsed CLL/SLL Revenue Market Share by Country (2021–2032)
Figure 26. Germany Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. France Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. U.K. Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Italy Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Russia Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Asia Pacific Duvelisib for Relapsed CLL/SLL Sales Market Share by Region (2021–2032)
Figure 32. Asia Pacific Duvelisib for Relapsed CLL/SLL Revenue Market Share by Region (2021–2032)
Figure 33. China Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Japan Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. South Korea Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. India Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Australia Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. China Taiwan Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Southeast Asia Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Latin America Duvelisib for Relapsed CLL/SLL Sales Market Share by Country (2021–2032)
Figure 41. Latin America Duvelisib for Relapsed CLL/SLL Revenue Market Share by Country (2021–2032)
Figure 42. Mexico Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Brazil Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Argentina Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Colombia Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Middle East and Africa Duvelisib for Relapsed CLL/SLL Sales Market Share by Country (2021–2032)
Figure 47. Middle East and Africa Duvelisib for Relapsed CLL/SLL Revenue Market Share by Country (2021–2032)
Figure 48. Turkey Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Saudi Arabia Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. UAE Duvelisib for Relapsed CLL/SLL Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Global Sales Market Share of Duvelisib for Relapsed CLL/SLL by Type (2021–2032)
Figure 52. Global Revenue Market Share of Duvelisib for Relapsed CLL/SLL by Type (2021–2032)
Figure 53. Global Duvelisib for Relapsed CLL/SLL Price (US$/Unit) by Type (2021–2032)
Figure 54. Global Sales Market Share of Duvelisib for Relapsed CLL/SLL by Application (2021–2032)
Figure 55. Global Revenue Market Share of Duvelisib for Relapsed CLL/SLL by Application (2021–2032)
Figure 56. Global Duvelisib for Relapsed CLL/SLL Price (US$/Unit) by Application (2021–2032)
Figure 57. Duvelisib for Relapsed CLL/SLL Value Chain
Figure 58. Channels of Distribution (Direct Vs Distribution)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
